---
author: mike
pubDatetime: 2024-05-02 18:57:50.331000
modDatetime: 
title: Q124 SYK earnings
slug: q124-syk-earnings
featured: false
ogImage: /assets/images/250_250.png
tags:
  - transcripts
  - earnings
  - healthcare
description: Earnings summary for Stryker
---
### Earnings Results
- Organic sales growth of 10%.
- MedSurg and Neurotechnology experienced double-digit growth.
- Orthopaedics and Spine had high single-digit growth.
- Quarterly adjusted EPS was $2.50, reflecting 16.8% growth compared to the first quarter of 2023.
- U.S. organic sales growth stood at 11.3%.
- International organic sales growth was at 6.6%.

### Future Guidance
- Full-year organic sales growth expectation increased to 8.5% to 9.5%.
- Adjusted EPS range for the full year updated to $11.85 to $12.05 a share.
- Target of 200 basis points of operating margin expansion by 2025.
- Anticipation of accelerated M&A activity throughout the year.

### Trends, Market Conditions, Sentiment
- Continuous strong commercial execution contributing to growth.
- Significant momentum in U.S. performance, particularly noted in Instruments, Medical, Endoscopy, Trauma, and Extremities, and Mako.
- International growth, particularly strong in the United Kingdom and Canada, as well as in emerging markets.
- Positive pricing initiatives, especially in MedSurg and Neurotech, contributing to favorable impacts.
- Procedural volumes remained strong, driven by continued adoption in robotic-assisted surgery, demographics, a stable pricing environment, and healthy patient activity.
- Demand for capital products remained healthy, with a continued elevated backlog across Endoscopy and Medical divisions.
- Recognition of Stryker as one of Fortune's 100 Best Companies to Work For, highlighting commitment to talent and culture.
- Publication of the annual comprehensive corporate responsibility report, emphasizing commitments and disclosures.

### Notable Quotes
- **Kevin Lobo**: "This reflects our team's continued strong commercial execution."
- **Glenn Boehnlein**: "Driven by our strong sales performance and margin expansion."
- **Jason Beach**: "Demand for our capital products remained healthy in the quarter with continued elevated backlog across our Endoscopy and Medical divisions."
- **Kevin Lobo**: "Our deal pipeline is strong, and we expect to be active over the course of the year."
- **Kevin Lobo**: "This guidance demonstrates the durability of our high growth and is a testament to our commercial strength and extensive pipeline of innovation across the company."

